PT1169021E - Composições e métodos para o tratamento de linfoma - Google Patents

Composições e métodos para o tratamento de linfoma Download PDF

Info

Publication number
PT1169021E
PT1169021E PT00920004T PT00920004T PT1169021E PT 1169021 E PT1169021 E PT 1169021E PT 00920004 T PT00920004 T PT 00920004T PT 00920004 T PT00920004 T PT 00920004T PT 1169021 E PT1169021 E PT 1169021E
Authority
PT
Portugal
Prior art keywords
mol
compositions
methods
cholesterol
lymphoma
Prior art date
Application number
PT00920004T
Other languages
English (en)
Portuguese (pt)
Inventor
Andreas H Sarris
Fernando Cabanillas
Patricia M Logan
Clive T R Burge
James H Goldie
Murray S Webb
Mayer D Lawrence
Original Assignee
Univ Texas
Hana Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Hana Biosciences Inc filed Critical Univ Texas
Publication of PT1169021E publication Critical patent/PT1169021E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT00920004T 1999-04-01 2000-03-31 Composições e métodos para o tratamento de linfoma PT1169021E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12744499P 1999-04-01 1999-04-01
US13719499P 1999-06-02 1999-06-02

Publications (1)

Publication Number Publication Date
PT1169021E true PT1169021E (pt) 2009-11-18

Family

ID=26825635

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00920004T PT1169021E (pt) 1999-04-01 2000-03-31 Composições e métodos para o tratamento de linfoma

Country Status (13)

Country Link
EP (3) EP2266537B1 (enExample)
JP (3) JP2002541088A (enExample)
AT (1) ATE442839T1 (enExample)
AU (1) AU777572B2 (enExample)
BR (1) BRPI0009448B8 (enExample)
CA (1) CA2366787C (enExample)
CY (1) CY1109641T1 (enExample)
DE (1) DE60042968D1 (enExample)
DK (2) DK2266537T3 (enExample)
ES (2) ES2333400T3 (enExample)
IL (4) IL145720A0 (enExample)
PT (1) PT1169021E (enExample)
WO (1) WO2000059473A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60042968D1 (de) * 1999-04-01 2009-10-29 Hana Biosciences Inc Zusammensetzungen und methoden zur behandlung lymphoma
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
ES2332584T3 (es) * 2001-03-27 2010-02-09 Phares Pharmaceutical Research N.V. Metodo y composicion para solubilizar un compuesto biologicamente activo con baja solubilidad en agua.
CN102379874B (zh) * 2002-05-17 2016-08-17 细胞基因公司 使用3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮用于治疗和控制多发性骨髓瘤的方法及组合物
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
FR2840203B1 (fr) * 2002-05-31 2004-08-27 Scherer Technologies Inc R P Composition pharmaceutique orale pour capsules molles contenant vinorelbine et methode de traitement
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
RU2252764C2 (ru) * 2003-03-04 2005-05-27 Российский научный центр рентгенорадиологии МЗ РФ Способ комплексного лечения лимфогранулематоза
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005011698A1 (en) * 2003-07-28 2005-02-10 Inex Pharmaceuticals Corporation Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia
KR101250127B1 (ko) * 2004-07-09 2013-04-02 바이엘 파마 악티엔게젤샤프트 Ｂ-세포 림프종의 치료를 위한 방사성표지된 안티-ｃｄ20항체와의 병용요법
WO2006020618A1 (en) * 2004-08-10 2006-02-23 Inex Pharmaceuticals Corporation Compositions and methods for treating leukemia
SI2200431T1 (sl) 2007-09-10 2016-10-28 Boston Biomedical, Inc. Sestave in metode za zdravljenje raka
NZ621433A (en) 2008-03-18 2015-10-30 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
JP2012506428A (ja) * 2008-10-24 2012-03-15 グルオウセステル プハルマセウトイカルス ガンの療法
IN2015DN04310A (enExample) * 2012-11-20 2015-10-16 Spectrum Pharmaceuticals
ES2824074T3 (es) * 2013-01-24 2021-05-11 Memorial Sloan Kettering Cancer Center Método para diagnosticar o tratar tumores mediante el uso de liposomas que contienen esfingomielina
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
TWI678213B (zh) * 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
SI26542A (sl) 2023-09-12 2025-03-31 Univerza V Ljubljani Nove liposomske formulacije in postopek za njihovo pripravo

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
GB9304745D0 (en) * 1993-03-09 1993-04-28 Oncholab Ab Use of pharmaceutical formulations
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
DE60042968D1 (de) * 1999-04-01 2009-10-29 Hana Biosciences Inc Zusammensetzungen und methoden zur behandlung lymphoma

Also Published As

Publication number Publication date
EP2266537B1 (en) 2014-09-03
AU777572B2 (en) 2004-10-21
ES2333400T3 (es) 2010-02-22
JP5981214B2 (ja) 2016-08-31
EP2266537A3 (en) 2012-02-22
CA2366787A1 (en) 2000-10-12
ATE442839T1 (de) 2009-10-15
AU4060600A (en) 2000-10-23
CA2366787C (en) 2013-03-12
IL212389A (en) 2015-07-30
IL145720A0 (en) 2002-07-25
BR0009448A (pt) 2002-01-08
BRPI0009448B1 (pt) 2018-09-11
EP1169021B1 (en) 2009-09-16
EP1985285A3 (en) 2009-08-12
DK2266537T3 (en) 2014-12-15
IL212390A (en) 2014-08-31
EP1985285A2 (en) 2008-10-29
JP2015071631A (ja) 2015-04-16
JP2002541088A (ja) 2002-12-03
DK1169021T3 (da) 2010-01-11
BRPI0009448B8 (pt) 2021-05-25
IL212390A0 (en) 2011-06-30
IL212389A0 (en) 2011-06-30
EP1169021A1 (en) 2002-01-09
EP2266537A2 (en) 2010-12-29
HK1152246A1 (en) 2012-02-24
IL145720A (en) 2011-05-31
ES2524141T3 (es) 2014-12-04
WO2000059473A1 (en) 2000-10-12
CY1109641T1 (el) 2014-08-13
DE60042968D1 (de) 2009-10-29
JP2012158602A (ja) 2012-08-23

Similar Documents

Publication Publication Date Title
IL212389A0 (en) Compositions comprising liposome-encapsulated vincristine for use in treating cancer
EP0943331A3 (en) Formulations containing oxaliplatin
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
AP9701019A0 (en) Phenylamino-substituted tricycle derivatives.
PL319833A1 (en) Compounds and composition for carrying active media
TR200800474T2 (tr) Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
EP1495754A3 (en) Method and composition for treating cancers
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
IL133824A (en) Tetrazole derivatives and medicaments containing the same
WO2003051275A3 (en) Benzodiazepine derivatives, preparation thereof and use thereof
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
GB2358395B (en) Tetrahydrofuran-adducted group 11 ß-diketonate complexes as source reagents for chemical vapor depostion
EP0924970A3 (en) Cleaning solution for electronic materials and method for using the same
NZ319138A (en) Composition containing cytochrome complex III and fenazaquin for combatting parasitic fungi
TW230775B (enExample)
AU695749B2 (en) Functional terpyridine metal complexes, a process for the preparation therof and oligonucleotide conjugates with terpyridine-metal complexes
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
CA2052640A1 (en) Method for destroying cyst of noxious plankton
ES2173464T3 (es) Preparacion de clorinas y bacterioclorinas con contenido en polieter.
WO1997013776A3 (fr) Nouveaux derives amines de 2', 3' didesoxyglycosides d'epipodophyllotoxine, leur procede de preparation, leur utilisation comme medicament et leur utilisation destinee aux traitements anticancereux
ZA987609B (en) Method for the synthesis of taxanes
CA2261802A1 (en) Use of xanomeline for treating bipolar disorder
WO2001062668A3 (en) Sulfur containing compounds
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis
AU5645899A (en) Plant fungus inhibiting compounds, process for their preparation, compositions containing them and their use in method for combatting plant fungi